Posters

      Assessment of potential neuroprotective effects of alkaloids in a human dopaminergic in vitro model of Parkinson’s disease

      Fares, M. B.; Mathis, C.; Kondylis, A.; Alijevic, O.; Sierro, N.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Mar 27, 2019
      Conference name

      14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD)
      Topic
      Summary

      Objectives: Over the past 50 years, retrospective epidemiological studies have consistently demonstrated an inverse association between the risk of developing Parkinson’s disease (PD) and history of tobacco use, with a two-fold risk decrease among tobacco smokers and snus users. In this study, we aimed to determine whether nicotine and other tobacco compounds could exert a neuroprotective role against alpha-Synuclein (α-Syn)-induced toxicity in a human dopaminergic neuronal model of PD.

      Methods: We differentiated human-induced pluripotent stem cells into dopaminergic neurons and then treated neuronal cultures with increasing doses of α-Syn preformed fibrils (PFF) or α-Syn monomers as controls. Various experimental conditions were tested using real-time and medium-throughput approaches: (i) neuronal adhesion/neurite outgrowth was assessed by impedance-based measurements using the xCELLigence® Real Time Cell Analyzer system, and (ii) mitochondrial respiration functions were evaluated using the Agilent Seahorse® analyzer.

      Results: Our results show that α-Syn PFF treatment induces dose-dependent neurodegeneration, neuritic pathology, and mitochondrial dysfunction in human dopaminergic neurons, thereby demonstrating the utility of this system to model molecular features of PD. Importantly, nicotine pretreatment for one hour was able to protect against multiple features of α-Syn PFF-induced toxicity in dopaminergic neurons in a dose-dependent manner. Current efforts are directed toward dissecting the mechanism through which nicotine exerts this observed beneficial effect.

      Conclusions: Our results provide a robust medium-throughput in vitro model of α-Syn PFF-induced toxicity in human dopaminergic neurons and pave the way toward a better understanding of mechanisms underlying the observed beneficial effects of nicotine in PD.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.